Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Debt for 5 consecutive years, with $108.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 1.48% to $108.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $108.2 million, a 1.48% decrease, with the full-year FY2025 number at $108.2 million, down 1.48% from a year prior.
  • Total Debt was $108.2 million for Q4 2025 at Rhythm Pharmaceuticals, down from $109.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $109.8 million in Q4 2024 to a low of $106.1 million in Q4 2023.
  • A 3-year average of $108.7 million and a median of $109.2 million in 2025 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: rose 3.45% in 2024, then decreased 1.48% in 2025.
  • Rhythm Pharmaceuticals' Total Debt stood at $106.1 million in 2023, then grew by 3.45% to $109.8 million in 2024, then dropped by 1.48% to $108.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Total Debt are $108.2 million (Q4 2025), $109.0 million (Q3 2025), and $109.8 million (Q2 2025).